NCT00217737 · OUTCOME

The Association Between Oxaliplatin Exposure, Allelic Variants in Candidate Genes, and Neurotoxicity

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer · Source last updated 2026-08-25

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Assessed at baseline, every 2 weeks while on treatment, up to 10 years

What was measured

The association between onset of neurotoxicity and oxaliplatin exposure will be assessed. The difference in neurotoxicity rates between patients with and without a given polymorphism will be evaluated.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: The association between onset of neurotoxicity and oxaliplatin exposure will be assessed. The difference in neurotoxicity rates between patients with and without a given polymorphism will be evaluated.
reporting Status: NOT_POSTED
time Frame: Assessed at baseline, every 2 weeks while on treatment, up to 10 years
title: The Association Between Oxaliplatin Exposure, Allelic Variants in Candidate Genes, and Neurotoxicity
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice